Game,

Thanks for encapsulating CGNH's financing so succinctly; my disappointment in these two events is that they fail to provide the funds necessary to conduct the head-to-head trials. This type of piecemeal financing will IMO lead the company down a pathway that will enable an investor like Saunders to acquire a majority interest in Cardiogenics at an undervalued price.

While such a strategy may well significantly reduce Dr G's equity in the company, it will I hope eventually provide the funds required to complete development and registration of the POC analyzer.

Ante